Fund 3
Vesalius Biocapital III

This fund, launched in May 2017 and finally closed in May 2019, targets later-stage European life science companies in drug development, medtech, diagnostics and eHealth / mHealth.

€120 million of commitments secured

The fund secured over €120 million of commitments; final closing took place in May 2019.



News for Vesalius Biocapital Fund 3

Topas Initiates Phase 2a Clinical Trial
read more
Memo Therapeutics: FDA Designation
read more
Memo Therapeutics: Positive Phase I Data
read more